Your browser doesn't support javascript.
loading
A Simple Cervicovaginal Epigenetic Test for Screening and Rapid Triage of Women With Suspected Endometrial Cancer: Validation in Several Cohort and Case/Control Sets.
Herzog, Chiara; Marín, Fátima; Jones, Allison; Evans, Iona; Reisel, Daniel; Redl, Elisa; Schreiberhuber, Lena; Paytubi, Sonia; Pelegrina, Beatriz; Carmona, Álvaro; Peremiquel-Trillas, Paula; Frias-Gomez, Jon; Pineda, Marta; Brunet, Joan; Ponce, Jordi; Matias-Guiu, Xavier; de Sanjosé, Silvia; Alemany, Laia; Olaitan, Adeola; Wong, Michael; Jurkovic, Davor; Crosbie, Emma J; Rosenthal, Adam N; Bjørge, Line; Zikan, Michal; Dostalek, Lukas; Cibula, David; Sundström, Karin; Dillner, Joakim; Costas, Laura; Widschwendter, Martin.
Affiliation
  • Herzog C; European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria.
  • Marín F; Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.
  • Jones A; Hereditary Cancer Group, Catalan Institute of Oncology, IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain.
  • Evans I; Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain.
  • Reisel D; Department of Women's Cancer, University College London, London, United Kingdom.
  • Redl E; Department of Women's Cancer, University College London, London, United Kingdom.
  • Schreiberhuber L; Department of Women's Cancer, University College London, London, United Kingdom.
  • Paytubi S; European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria.
  • Pelegrina B; Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.
  • Carmona Á; European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Innsbruck, Austria.
  • Peremiquel-Trillas P; Institute for Biomedical Aging Research, Universität Innsbruck, Innsbruck, Austria.
  • Frias-Gomez J; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Pineda M; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Brunet J; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Ponce J; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Matias-Guiu X; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • de Sanjosé S; Hereditary Cancer Group, Catalan Institute of Oncology, IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain.
  • Alemany L; Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain.
  • Olaitan A; Hereditary Cancer Group, Catalan Institute of Oncology, IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain.
  • Wong M; Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain.
  • Jurkovic D; Hereditary Cancer Group, Catalan Institute of Oncology, IDIBGI, Girona, Spain.
  • Crosbie EJ; Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain.
  • Rosenthal AN; Department of Gynecology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Bjørge L; Consortium for Biomedical Research in Cancer-CIBERONC, Carlos III Institute of Health, Madrid, Spain.
  • Zikan M; Department of Pathology, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Dostalek L; ISGlobal, Barcelona, Spain.
  • Cibula D; Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Sundström K; Consortium for Biomedical Research in Epidemiology and Public Health-CIBERESP, Carlos III Institute of Health, Madrid, Spain.
  • Dillner J; University College Hospital, London, United Kingdom.
  • Costas L; University College Hospital, London, United Kingdom.
  • Widschwendter M; University College Hospital, London, United Kingdom.
J Clin Oncol ; 40(33): 3828-3838, 2022 11 20.
Article de En | MEDLINE | ID: mdl-36001862
PURPOSE: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival. METHODS: We developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86). RESULTS: We describe the Women's cancer risk IDentification - quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology. CONCLUSION: The WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du col de l'utérus / Tumeurs de l'endomètre / Infections à papillomavirus Type d'étude: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limites: Female / Humans Langue: En Journal: J Clin Oncol Année: 2022 Type de document: Article Pays d'affiliation: Autriche Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du col de l'utérus / Tumeurs de l'endomètre / Infections à papillomavirus Type d'étude: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limites: Female / Humans Langue: En Journal: J Clin Oncol Année: 2022 Type de document: Article Pays d'affiliation: Autriche Pays de publication: États-Unis d'Amérique